These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24660624)

  • 1. Activation of anti-HBV immune activity by DNA vaccine via electroporation using heat shock proteins as adjuvant.
    Xu Y; Wang Y; Zhao B; Zhang X; Fan H; Li X; Meng S
    Sheng Wu Gong Cheng Xue Bao; 2013 Dec; 29(12):1765-75. PubMed ID: 24660624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice.
    Wang S; Qiu L; Liu G; Li Y; Zhang X; Jin W; Gao GF; Kong X; Meng S
    Vaccine; 2011 Aug; 29(37):6342-51. PubMed ID: 21600951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Enhancement of cellular and humoral immune responses of HBV DNA vaccine by HSP70 and gp96].
    Wang Y; Wang S; Zhang X; Li Y; Zhao S; Meng S
    Sheng Wu Gong Cheng Xue Bao; 2011 May; 27(5):790-8. PubMed ID: 21845846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine.
    Li X; Yang X; Li L; Liu H; Liu J
    Vaccine; 2006 Apr; 24(16):3321-31. PubMed ID: 16472546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
    Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
    Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice.
    Buchmann P; Dembek C; Kuklick L; Jäger C; Tedjokusumo R; von Freyend MJ; Drebber U; Janowicz Z; Melber K; Protzer U
    Vaccine; 2013 Feb; 31(8):1197-203. PubMed ID: 23306359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.
    Li J; Ge J; Ren S; Zhou T; Sun Y; Sun H; Gu Y; Huang H; Xu Z; Chen X; Xu X; Zhuang X; Song C; Jia F; Xu A; Yin X; Du SX
    Vaccine; 2015 Aug; 33(35):4247-54. PubMed ID: 25858855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.
    Reynolds TD; Buonocore L; Rose NF; Rose JK; Robek MD
    J Virol; 2015 Oct; 89(20):10407-15. PubMed ID: 26246574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of immune responses induced by therapeutic vaccination with cross-reactive antigens in a humanized hepatitis B surface antigen transgenic mouse model.
    Bourgine M; Dion S; Godon O; Guillen G; Michel ML; Aguilar JC
    Virology; 2012 Aug; 430(1):10-9. PubMed ID: 22591777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing the potency of HBV DNA vaccines using fusion genes of HBV-specific antigens and the N-terminal fragment of gp96.
    Yan J; Liu X; Wang Y; Jiang X; Liu H; Wang M; Zhu X; Wu M; Tien P
    J Gene Med; 2007 Feb; 9(2):107-21. PubMed ID: 17256801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional aspects of intrahepatic hepatitis B virus-specific T cells induced by therapeutic DNA vaccination.
    Brass A; Frelin L; Milich DR; Sällberg M; Ahlén G
    Mol Ther; 2015 Mar; 23(3):578-90. PubMed ID: 25492563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models.
    Su J; Brunner L; Ates Oz E; Sacherl J; Frank G; Kerth HA; Thiele F; Wiegand M; Mogler C; Aguilar JC; Knolle PA; Collin N; Kosinska AD; Protzer U
    J Hepatol; 2023 Apr; 78(4):717-730. PubMed ID: 36634821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunological and virological efficacy against HBV chronic infection of the therapeutic vaccine composed of HBV core plus PreS1 in HBV transgenic mice].
    Li MZ; Chen XC; Zhou BP; Le XH; Xu LM; Wang HS
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Sep; 17(3):277-9. PubMed ID: 15340577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential.
    Riedl P; Wieland A; Lamberth K; Buus S; Lemonnier F; Reifenberg K; Reimann J; Schirmbeck R
    J Immunol; 2009 Jul; 183(1):370-80. PubMed ID: 19542448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering enhancement of the immune response to HBV DNA vaccine in mice by the use of LIGHT gene adjuvant.
    Zhang Y; Jiang W; Fan Y; Wen J; Hao W; Qian M
    J Virol Methods; 2008 Nov; 153(2):142-8. PubMed ID: 18722475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune modulator and antiviral potential of dendritic cells pulsed with both hepatitis B surface antigen and core antigen for treating chronic HBV infection.
    Akbar SM; Yoshida O; Chen S; Cesar AJ; Abe M; Matsuura B; Hiasa Y; Onji M
    Antivir Ther; 2010; 15(6):887-95. PubMed ID: 20834101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine.
    Zhou C; Peng G; Jin X; Tang J; Chen Z
    Clin Immunol; 2010 Nov; 137(2):190-8. PubMed ID: 20692873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A non-human hepadnaviral adjuvant for hepatitis C virus-based genetic vaccines.
    Levander S; Sällberg M; Ahlén G; Frelin L
    Vaccine; 2016 May; 34(25):2821-33. PubMed ID: 27109565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HBcAg18-27 epitope fused to HIV-Tat 49-57 adjuvanted with CpG ODN induces immunotherapeutic effects in transgenic mice.
    Wang S; Han Q; Zhang N; Chen J; Liu Z; Zhang G; Li Z
    Immunol Lett; 2010 Jan; 127(2):143-9. PubMed ID: 19883689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Suppression of the antigen-specific T cell immune response by co-immunization with the HBV DNA vaccine and recombinant HBsAg].
    Du X; Wang J; Kang Y; Xiao W; Zhao G; Wang B
    Wei Sheng Wu Xue Bao; 2009 Jul; 49(7):938-42. PubMed ID: 19873759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.